The post Emergence Of Trey Yesavage A Major Boon To Future Of Blue Jays appeared on BitcoinEthereumNews.com. Toronto Blue Jays pitcher Trey Yesavage celebrates in his dugout during the seventh inning in Game 5 of baseball’s World Series against the Los Angeles Dodgers, Wednesday, Oct. 29, 2025, in Los Angeles. (AP Photo/Ashley Landis) Copyright 2025 The Associated Press. All rights reserved The Toronto Blue Jays and their fans almost certainly are still in a collective state of shock. They did everything but win the World Series, outscoring and arguably outplaying the mighty Los Angeles Dodgers, somehow falling just short of putting them away countless times. This matchup was incorrectly billed as a stereotypical David vs. Goliath kind of deal. That’s just not fair to the Blue Jays. The Dodgers had to play in the wild card round, not the Jays. The Jays had home field advantage, not the Dodgers. Both teams had great offenses, but Toronto’s was more well-rounded, made way more contact and wasn’t quite as reliant on its transcendent superstar. The Jays actually had a bullpen. One area in which the Dodgers had a distinct advantage was in the starting rotation. They set out to use their four ace starters – Shohei Ohtani, Yoshinobu Yamamoto, Blake Snell and Tyler Glasnow – as often as possible, in starting and relief roles. And the Jays had no chance to match them. But they came oh so close to doing so, in large part to the emergence of rookie Trey Yesavage. Yesavage was the Blue Jays’ 1st round pick in the 2024 draft, the 20th overall selection, out of East Carolina University. To say that he rode the bullet train to the major leagues would be an understatement. He had all of 98 innings worth of minor league seasoning, in which he posted a gaudy 160/41 K/BB ratio. He then accrued all of 14 major league innings after… The post Emergence Of Trey Yesavage A Major Boon To Future Of Blue Jays appeared on BitcoinEthereumNews.com. Toronto Blue Jays pitcher Trey Yesavage celebrates in his dugout during the seventh inning in Game 5 of baseball’s World Series against the Los Angeles Dodgers, Wednesday, Oct. 29, 2025, in Los Angeles. (AP Photo/Ashley Landis) Copyright 2025 The Associated Press. All rights reserved The Toronto Blue Jays and their fans almost certainly are still in a collective state of shock. They did everything but win the World Series, outscoring and arguably outplaying the mighty Los Angeles Dodgers, somehow falling just short of putting them away countless times. This matchup was incorrectly billed as a stereotypical David vs. Goliath kind of deal. That’s just not fair to the Blue Jays. The Dodgers had to play in the wild card round, not the Jays. The Jays had home field advantage, not the Dodgers. Both teams had great offenses, but Toronto’s was more well-rounded, made way more contact and wasn’t quite as reliant on its transcendent superstar. The Jays actually had a bullpen. One area in which the Dodgers had a distinct advantage was in the starting rotation. They set out to use their four ace starters – Shohei Ohtani, Yoshinobu Yamamoto, Blake Snell and Tyler Glasnow – as often as possible, in starting and relief roles. And the Jays had no chance to match them. But they came oh so close to doing so, in large part to the emergence of rookie Trey Yesavage. Yesavage was the Blue Jays’ 1st round pick in the 2024 draft, the 20th overall selection, out of East Carolina University. To say that he rode the bullet train to the major leagues would be an understatement. He had all of 98 innings worth of minor league seasoning, in which he posted a gaudy 160/41 K/BB ratio. He then accrued all of 14 major league innings after…

Emergence Of Trey Yesavage A Major Boon To Future Of Blue Jays

Toronto Blue Jays pitcher Trey Yesavage celebrates in his dugout during the seventh inning in Game 5 of baseball’s World Series against the Los Angeles Dodgers, Wednesday, Oct. 29, 2025, in Los Angeles. (AP Photo/Ashley Landis)

Copyright 2025 The Associated Press. All rights reserved

The Toronto Blue Jays and their fans almost certainly are still in a collective state of shock. They did everything but win the World Series, outscoring and arguably outplaying the mighty Los Angeles Dodgers, somehow falling just short of putting them away countless times.

This matchup was incorrectly billed as a stereotypical David vs. Goliath kind of deal. That’s just not fair to the Blue Jays. The Dodgers had to play in the wild card round, not the Jays. The Jays had home field advantage, not the Dodgers. Both teams had great offenses, but Toronto’s was more well-rounded, made way more contact and wasn’t quite as reliant on its transcendent superstar. The Jays actually had a bullpen.

One area in which the Dodgers had a distinct advantage was in the starting rotation. They set out to use their four ace starters – Shohei Ohtani, Yoshinobu Yamamoto, Blake Snell and Tyler Glasnow – as often as possible, in starting and relief roles. And the Jays had no chance to match them. But they came oh so close to doing so, in large part to the emergence of rookie Trey Yesavage.

Yesavage was the Blue Jays’ 1st round pick in the 2024 draft, the 20th overall selection, out of East Carolina University. To say that he rode the bullet train to the major leagues would be an understatement. He had all of 98 innings worth of minor league seasoning, in which he posted a gaudy 160/41 K/BB ratio. He then accrued all of 14 major league innings after being recalled in September.

He then became the club’s co-ace along with Kevin Gausman in the postseason, clearly outshining his much more experienced rotation-mate. A 39/11 K/BB ratio along with a more than respectable 3.58 ERA 27 2/3 innings certainly catches the eye. It was Yesavage, not Gausman, who was summoned to pitch in relief in addition to his starter’s workload in the World Series, like the Dodger stars, and he was up to the task.

This is a huge development for the Blue Jays, who simply lack the starting pitching depth of most World Series contenders. Gausman is a legit staff ace, albeit one who is overly dependent upon his splitter for his success. Max Scherzer and Shane Bieber, their postseason contributions notwithstanding, have uncertain futures. Chris Bassitt is a free agent, and Jose Berrios was unuseable by season’s end. Eric Lauer is a nice complementary piece as a swingman, but it would be unwise to expect more from him.

Yesavage is a potential staff alpha, with an out-pitch splitter but more, featuring a fastball and slider that also flash well above average, all coming out of a deceptive over-the-top delivery that has some Tim Lincecum to it. There’s no reason to believe that Yesavage won’t quickly settle in at the very top of the Blue Jay rotation and stay a while.

The role of the starting pitcher once again is changing at the major league level, with the importance of the durable workhorse increasing. For a while there, teams were loath to let starters go a third time around the order and were often into their bullpens by choice by the 5th inning. The pendulum has begun to swing in the other direction.

The number of MLB ERA qualifiers (162 or more innings pitched) has begun to creep upward in recent seasons after years of steep decline. In any single game, the third time around the order theory makes some sense, but over a full season the bullpen churn is too much for a team to bear, and can lead to pitching staff collapse.

Starting pitcher development has also begun to change. Yes, innings limits still exist, but they’re not as etched in stone as they once were. What good is it for a club to be ultra-careful and then watch a pitcher spend half of their control years on the major league disabled list, like, say, Hunter Greene. Get a guy to the major leagues, let him pitch at a high level and max out the value of his control years. Sure, the pitcher could still get hurt, but be aggressive within reason.

The Jays did just that with Yesavage down the stretch, and it came thisclose to resulting in a World Series championship. Starting pitching remains the coin of the realm, and while it ultimately delivered a World Series title to the Dodgers, the Jays’ new young ace did everything within his power to fight them off.

Source: https://www.forbes.com/sites/tonyblengino/2025/11/05/emergence-of-trey-yesavage-a-major-boon-to-future-of-blue-jays/

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.13574
$0.13574$0.13574
+5.08%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23